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INTRODUCTION
In recent years, steroidal ophthalmic solutions in
addition to topical non-steroidal anti-inflammatory
drugs (NSAIDs) such as diclofenac or bromfenac
are administered for approximately 1 month after
uneventful cataract surgery (phaco-emulsification
and aspiration plus intraocular lens implantation,
PEA+IOL implantation) in order to reduce an inflam-
matory reaction. From the perspective of infection
prophylaxis, however, postoperative steroidal oph-
thalmic solutions might be best avoided after inter-
nal ocular surgery because these drugs have a non-
specific immunosuppressive effect. If it is possible,
only NSAIDs ought to be administered after internal
ocular surgeries as a postoperative anti-inflammatory
medication.
Meanwhile, over more than a decade, the surgi-
cal technique of PEA+IOL implantation has been re-
fined dramatically, and sophisticated surgical ma-
chines and several types of biocompatible IOLs have
been developed. The chance of developing a strong
inflammatory reaction such as a fibrin aggregation
in the anterior chamber or a widespread corneal
edema after a PEA+IOL implantation are low. In
this study, we evaluated the necessity of topical ster-
oids in the early postoperative stage following an un-
eventful PEA+IOL implantation by examining the
visual acuity, intraocular pressure (IOP), corneal en-
dothelial cell density and anterior chamber flare
value in various perioperative periods.
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MATERIALS AND METHODS
1. Materials
A total of 21 patients with age-related cataract
(28 eyes) were recruited for this study after obtain-
ing informed consent under the approval of Mino
Tanaka Hospital ethics committee. All patients had
undergone an uneventful PEA+IOL implantation at
Mino Tanaka Hospital in Tokushima Prefecture, Ja-
pan between March and September 2007. Patinets
with uveitis, glaucoma, exfoliation syndrome, small
pupil or poorly controlled diabetes (i.e. hemoglobin
A1c value were 8.0% or over) were excluded be-
cause of the possible risk of a blood aqueous barrier
breakdown. The study included 12 eyes of 8 males
and 16 eyes of 13 females, the mean age of partici-
pants was 76.26.4 years old.
2. Methods
All participants were prospectively evaluated by
randomizing into 2 groups : steroid group (12 eyes
of 11 patients) and non-steroid group (16 eyes of 10
patients).
1) Perioperative medications
In both groups, 0.3% moxifloxacin (MFLX) and
0.1% chloramphenicol colistin methanesulfonic acid
(CP/C) ophthalmic solutions were applied 4 times
daily for 3 days prior to surgery, and bromfenac so-
dium (BF) was applied every 20 minutes 2 hours
prior to surgery. From the day after surgery, in
the steroid group, patients were adminiseterd 0.1%
fluorometholone and BF 4 times and twice daily, re-
spectively, in addition to the same dosage of MFLX
and CP/C as administered in the preoperative stage.
The non-steroid group patients were administered
the above 2 antimicrobial agents and BF were ap-
plied 4 times and twice daily, respectively.
2) Surgical procedure
All surgeries were performed in a standardized
manner by 3 Japanese ophthalmological specialists
in alternate shifts. The pupil was dilated with tropi-
camide and phenylephrine hydrochloride ophthal-
mic solutions. The ocular surface was rinsed with
16 times attenuation povidone-iodine. Under the
topical 4% oxybuprocaine drops administration, a
conjunctival incision was made, and a sub-Tenon’s
capsule anesthesia with 2 ml of 2% lidocaine hydro-
chloride was applied. Continuous curvilinear cap-
sulorrhexis and hydrodissection were then per-
formed. This was followd by phaco-emulsification
and aspiration via phaco chop methodsTM by using
Infinity Vision System (Alcon Lab, Fort Worth,
Texas, USA), and implantation of acrylic foldable
IOLs (SA30AT, SA60AS, SN60AT, SN60WF,
and ZA9003) implantation through a 2.8 -- 3.5 mm
sclerocorneal incision using the injector system rec-
ommended for each lens. A subconjunctival injection
of approximately 0.5 ml phosphoric acid dexametha-
sone was injected was applied at the end of the sur-
gery in the steroid group.
3) Main outcome measure
For all patients, the best-corrected visual acuity
(BCVA), IOP, corneal endothelial cell density, and
anterior chamber flare values (photon counts/msec,
KOWA, FM-600) were examined at periopera-
tively, i.e., from 2 hours before surgery to 1 month
after it. We defined visual acuity as “improve” when
it recovered up to two phases, “worse” when it de-
creased to two phases, and “no change” when its
value were between the improved and worse visual
acuities. Fluorescein fundus angiography was per-
formed only when cystoid macular edema (CME)
was suspected to worsen the visual acuity to less
than 0.7.
4) Statistical analysis
A student t-test was used for statistical analysis in
epidemiological data, corneal endothelial cell den-
sity, and anterior chamber flare value.
RESULTS
1. Epidemiological data (Table 1)
Table 1 shows the patient profiles. No significant
differences were observed in the age, visual acuity,
Table 1 No significant differences were noted between the 2
groups with regard to any of the parameters. Nuclear sclerosis
was determined according to the Emery-Little classification.
Steroid group Non-steroidgroup P value
Age (y) 76.76.4 76.06.1 0.78
Pre-ope BCVA* 0.540.27 0.560.28 0.86
Pre-ope IOP**
(mmHg) 12.3
2.4 12.32.9 0.98
Degree of nuclear
sclerosis 2.5
0.7 2.30.6 0.47
Surgery time (min) 17.56.3 14.75.8 0.27
PEA time***(s) 35.216.6 35.619.9 0.95
* : Preoperative best corrected visual acuity
** : Preoperative intra ocular pressure
*** : Phaco-emulsification and aspiration time
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IOP, degree of nuclear sclerosis, operation time, and
PEA time between the two groups.
2. Visual acuity (Figure 1)
At one month after operation, the BCVA improved
in 9 eyes (76%) in the steroid group and 12 eyes
(75%) in the non-steroid group, i.e., 21 eyes (75%)
in total, improved. The BCVA remained constant in
3 eyes (24%) in the former group and 4 eyes (25%)
in the latter group. The BCVA did not deteriorate
in any patient.
3. IOP
At day 1, 2 weeks and 1 month after operation,
the mean IOPs in the steroid group were 14.95,
11.36 and 11.00 mm Hg, respectively, and those in
the non-steroid group were 13.31, 11.19, and 9.71
mm Hg, respectively.
4. Corneal endothelial cell density (Figure 2)
At 7 days after operation, the rate of reduction in
the corneal endothelial cell density was 11.9% in the
steroid group and 8.4% in the non-steroid gruop.
Furthermore, no significant difference was noted be-
tween the 2 groups with regard to those rate at 1
month after operation (P=0.27), it was 6.7% and 9.6%
in the steroid and non-steroid groups respectively.
5. Anterior chamber flare value (Figure 3)
No significant difference was detected in the an-
terior chamber flare value between the 2 groups at
day 1(P=0.64), days 7(P=0.40), and 1 month (P=
0.39) after operation.
Figure 3 No significant difference was found in the anterior
flare values between the 2 groups during every postoperative
stages was found.
* : Preoperative best corrected visual acuity
** : Postoperative best corrected visual acuity
Figure 1 BCVA remained unchanged in 3 eyes ; 1 of which
had a corneal leukoma and 2 had retinal diseases.
Figure 2 No significant difference was found in the rate of re-
duction of corneal endothelial cell density between the 2 groups
found at 1 month after operation.
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6. CME
Although the BCVA worsened in 3 eyes of 2 pa-
tients, CME was not found in any of patients. In the
2 eyes of the 1 patient, chorioretinal atrophy was
considered to be responsible for the deterioration
of the BCVA. In 1 eye of another patient, corneal
leukoma was related to the deterioration of the
BCVA. Therefore, fluorescein fundus angiography
was not deemed to be necessary in any of patients.
DISCUSSION
Recently, topical antimicrobials and steroids are
commonly used as perioperative medications for in-
ternal ophthalmic surgeries in Japan, and the use of
steroids has not been questioned. Topical antimi-
crobials are administered to prevent postoperative
infections. Endophthalmitis, although the incident is
rare (incidence, 0.048% to 0.36% (1 -3)), is one of the
most vision-threatening complications that should
be avoided after PEA+IOL implantation, because it
can cause a rapid visual loss. The causative patho-
gens are likely to be indigenous gram-positive cocci
present on the ocular surface : coagulase-negative
Staphylococcus (CNS) mainly on Staphylococcus epi-
dermidis, Staphylococcus aureus, and Enterococcus
facealis . Therefore, fluoroquinolone, chlorampheni-
col, and cefem antimicrobial ophthalmic solutions
are recommended to use as a perioperative medi-
cations for the disinfection of the ocular surface
prior to cataract surgery. However, it is impossible
to completely sterilize the ocular surface during
surgery, and bacteria contamination of surgical
specimens of the aqueous humour has been re-
ported (4, 5). Additionally, tears can flow into the
anterior chamber in the early postoperative stage
even if the sclerocorneal incision is well made. Con-
sequently, it seems that the perioperative use of an-
timicrobial ophthalmic solutions is necessary.
Although topical steroid treatment after intracap-
sular cataract extraction (ICCE) was reported to be
effective against postoperative corneal edema (6),
these drugs may induce a secondary glaucoma and
delay epithelial wound healing ; additionally, they
also have non-specific immunosuppressive effects.
From the viewpoint of infection prophylaxis, there
is an idea that enough anti-inflammatory effect could
be obtained by topical NSAIDs only. Because the
surgical trauma after recent small incision of PEA+
IOL implantation is less than that caused by older
methods of extra capsular cataract extraction and
ICCE, the necessity of topical steroids as postop-
erative anti-inflammatory medication is ought to be
reconsidered.
With regard to the anterior chamber flare values
after PEA+IOL implantation, some reports (7, 8)
have stated that these values do not significantly
differ between the patients treated with a single
NSAID and those treated with a single steroid dur-
ing the perioperative periods. Moreover, on com-
paring of 3 groups ; namely, those administered a
combination of steroids and NSAID, a single ster-
oid, and a single NSAID, Kato, et al (9). reported
that no significant difference existed in the anterior
chamber flare values during the periods from the
day after the surgery to 3 months after surgery. We
believe that the discrepancy in the measurement of
the anterior chamber flare value and in the total ob-
jects number may have caused the difference results
in the results, hence, and the influence of parame-
ter like BCVA, IOP, endothelial cell density, and an-
terior chamber flare value on each other ought to
be considered. Our results that no significant differ-
ences exist between the 2 groups with regard to all
the criteria measured, as described earlier, provide
supportive evidence of similar postoperative ante-
rior chamber flare values in the 2 groups.
With regard to CME following PEA+IOL implan-
tation, Miyake, et al (10) reports that CME is less
frequent in the group using single NSAID than in
the group using a single steroid. They also report
that the anterior chamber flare value is higher in pa-
tients with CME than the patients without CME.
However, in our study, CME cases were not ob-
served in either group. This may be attributed to the
decreased surgical trauma inflicted by recent PEA+
IOL implantation technique. Additionally, some re-
ports (11 - 13) described that no significant differ-
ence existed in the occurrence of posterior capsu-
lar opacification after PEA+IOL implantation among
the groups administered a single NSAID, a single
steroid, or a combination of these drugs. Although
we did not check for posterior capsular opacification
in our study because this complication commonly
occurs in several years after the operation, it seems
that in the long term, the topical NSAIDs are as ef-
fective as topical steroids after PEA+IOL implanta-
tion.
In conclusion, it is suggested that topical steroi-
dal medication is not absolutely essential after un-
eventful small-incision PEA+IOL implantation be-
cause the postoperative inflammation is very mild.
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We believe that non-use of topical steroids during
the perioperative periods of intraocular surgery
such as PEA+IOL implantation may prevent the oc-
currence of severe infectious diseases such as en-
dophthalnitis.
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